Muscle Spasticity Market, by Drug Type (Baclofen, Botulinum Toxin, Diazepam, Tizanidine, Dantrolene Sodium, and Others), by Route of Administration (Oral, Intramuscular, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Dec 2021

Code : CMI4827

Pages :192

Formats :

Excel and PDF

Industry : Pharmaceutical

Muscle Spasticity MarketSize and Trends

The global spasticity market is estimated to be valued at US$ 4,167.6 million in 2021 and is expected to exhibit a CAGR of 8.9% during the forecast period (2021-2028).

Increasing prevalence of stroke, multiple sclerosis, and brain injury is expected to drive the market growth during the forecast period.

An increase in the prevalence of strokes, multiple sclerosis, and brain injuries is expected to drive the market growth during the forecast period. For instance, according to an article published in ‘International Journal of Neurorehabilitation’, in 2016, in America, approximately 795,000 people experience stroke each year, with around 610,000 of those being reported to be the first incidence of stroke. Research into spasticity prevalence in first stroke survivors indicates that up to 20-43% may experience some spasticity as a result of the injury.

Increasing research and development for developing effective therapies is expected to drive the market growth during the forecast period.

The increasing research and development of new and effective therapies for the treatment of muscle spasticity is expected to drive the market growth during the forecast period. For instance, in November 2021, Aditum Bio, the biotech investment firm for BioMedical Research, announced the formation of Motric Bio, a portfolio company developing a new therapy for spasticity associated with neurological injuries and disease. Current treatments target the central nervous system (CNS), with many causing cardiovascular and neurological side effects. Myosin-2 inhibitor molecule, which is to be developed by Motric Bio, has shown selectivity to fast skeletal myosin-2, with practically no inhibition of cardiac and smooth muscle myosins. This could lead to greater efficacy and fewer side effects than the current standard of care.

Figure 1.Global Muscle Spasticity Market Share (%) in Terms of Value, By Drug Type, 2021